Business
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral
About this update from Ac Immune Sa
[{"type":"text","content":"AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060, and ACI-19626 Lausanne, Switzerland, July 16, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced three oral presentations highlighting its precision medicine pipeline at the annual Alzheimer’s Association International Conference (AAIC 2024), taking place in Philadelphia, PA, on July 28 - August 1, 2024. Presentation details (all times are EDT) Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43-PET tracer Date: Monday, July 29, 2024 | 2:50 PM – 3:00 PMLocation: Hall A - Pennsylvania Convention Center Presenter: Tamara Seredenina, PhD (AC Immune) Active immunotherapy, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies Date: Tuesday, July 30, 2024 | 9:40 AM – 9:50 PMLocation: 201 ABC - Pennsylvania Convention CenterPresenter: Emma Fiorini, PhD (AC Immune) A new class of neurodegenerative disease-fighting drugs: morADC (Morphomer®- Antibody Drug Conjugates)Date: Wednesday, July 31, 2024 | 8:07 AM – 8:14 AMLocation: 118 ABC - Pennsylvania Convention Center Presenter: Madiha Derouazi, PhD (AC Immune) Poster details#18 Comparative analysis of clinical endpoint progression rates in sporadic Alzheimer’s disease and Down Syndrome-related Alzheimer’s diseaseDate: Tuesday, July 30, 2024 | 8:00 AM – 4:15 PMLocation: Exhibit Hall - Pennsylvania Convention CenterPresenter: Michael Rafii, MD, PhD (Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA) About AC Immune SAAC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic ...